GlassScriptPhysician profile
Peter K Fung
NPI 1871519561
$3,869.33
in general payments reported to CMS, 2019-2025
34 companies · $1,067 in 2025
The $1,067 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $537 · 2021: $520 · 2022: $304 · 2023: $45.12 · 2024: $473 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $472.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $462.92 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $373.02 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $328.36 | 2019-2022 | |
| Pfizer INC. | $287.14 | 2019-2025 | |
| Amgen INC. | $248.11 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $223.18 | 2019-2022 | |
| Cvrx, INC. | $201.36 | 2024-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $157.31 | 2021-2025 | |
| Emd Serono, INC. | $124.26 | 2019 | |
| Amarin Pharma, INC. | $108.26 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $101.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $77.91 | 2019-2020 | |
| Boston Scientific Corporation | $76.91 | 2022 | |
| Esperion Therapeutics, INC. | $68.48 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.91 | 2020-2021 | |
| Edwards Lifesciences Corporation | $55.54 | 2020 | |
| Arbor Pharmaceuticals, INC. | $52.27 | 2021-2022 | |
| Recor Medical INC | $48.72 | 2024 | Paradise Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.69 | 2019-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $39.10 | 2025 | Assure Wcd |
| Xeris Pharmaceuticals, INC. | $35.57 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $30.54 | 2025 | Uptravi, Opsynvi |
| Abiomed | $26.26 | 2023 | Impella |
| Janssen Biotech, INC. | $20.16 | 2024 | Stelara |
| Kiniksa Pharmaceuticals, LTD. | $18.80 | 2021 | |
| Glaxosmithkline, LLC. | $18.79 | 2025 | Shingrix |
| Angiodynamics, INC. | $17.26 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2021 | |
| Gilead Sciences, INC. | $15.98 | 2019 | |
| Amryt Pharma Holdings LTD | $15.13 | 2021 | |
| Astellas Pharma US INC | $14.99 | 2019 | |
| Irhythm Technologies, INC. | $14.35 | 2021 | |
| Tactile Systems Technology INC | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.